Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC decreased its position in Illumina, Inc. (NASDAQ:ILMNFree Report) by 3.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 7,294 shares of the life sciences company’s stock after selling 230 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Illumina were worth $1,001,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. State of Wyoming acquired a new stake in shares of Illumina in the second quarter valued at $32,000. Quent Capital LLC raised its position in shares of Illumina by 71.2% during the third quarter. Quent Capital LLC now owns 250 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 104 shares during the period. ST Germain D J Co. Inc. acquired a new stake in shares of Illumina during the second quarter worth $36,000. Riverview Trust Co raised its position in shares of Illumina by 203.5% during the third quarter. Riverview Trust Co now owns 261 shares of the life sciences company’s stock worth $36,000 after purchasing an additional 175 shares during the period. Finally, WFA of San Diego LLC acquired a new stake in shares of Illumina during the second quarter worth $37,000. Institutional investors and hedge funds own 92.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ILMN shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $258.00 target price on shares of Illumina in a research report on Friday. Piper Sandler cut their target price on Illumina from $200.00 to $190.00 and set an “overweight” rating on the stock in a research report on Monday, November 13th. StockNews.com raised Illumina from a “hold” rating to a “buy” rating in a research report on Wednesday, February 7th. Guggenheim initiated coverage on Illumina in a research report on Thursday, December 14th. They set a “buy” rating and a $155.00 price target on the stock. Finally, Bank of America lowered Illumina from a “neutral” rating to an “underperform” rating and dropped their price target for the company from $140.00 to $100.00 in a research report on Tuesday, December 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $166.95.

Get Our Latest Stock Analysis on Illumina

Illumina Stock Performance

Shares of ILMN stock opened at $139.96 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $238.55. The stock’s 50-day moving average is $135.76 and its two-hundred day moving average is $137.24. The firm has a market cap of $22.23 billion, a P/E ratio of -19.07, a PEG ratio of 25.05 and a beta of 1.22.

Illumina (NASDAQ:ILMNGet Free Report) last released its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.13. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.14 EPS. Analysts predict that Illumina, Inc. will post 1.03 earnings per share for the current fiscal year.

Illumina Profile

(Free Report)

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Further Reading

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.